| abstract |
Diseases associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals in a subject by administering carotenoid structural analogs, alone or in combination with other carotenoid analogs, to the subject in the form of co-antioxidant formulations. To inhibit and / or alleviate the onset of The analog or analog combination is administered to reduce the risk that the subject will develop a disease associated with reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals. Analogs or analog combinations can be administered to a subject to inhibit and / or alleviate ischemic reperfusion injury. Analogs or analog combinations can be administered to a subject to inhibit and / or alleviate liver disease. Analogs or analog combinations can be administered to a subject to inhibit and / or alleviate cancer. Analogs or analog combinations can be administered to a subject to inhibit and / or alleviate cardiac arrhythmias and / or sudden cardiac death. Analogs or analog combinations can be administered to a subject to inhibit and / or alleviate diseases including the production of reactive oxygen species, reactive nitrogen species, radicals and / or non-radicals. In one embodiment, water soluble and / or water dispersible astaxanthin analogs are particularly effective. The present invention also includes pharmaceutical compositions comprising carotenoid analogs alone or carotenoid analog combinations. |